oasis-1 oral semaglutide 50 mg obesity nejm 2023 A Review of the in Adults with Overweight or (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity 50 mg of oral #semaglutide

Therap Clin Risk Manag 5 : 617626

One of the key benefits of tirzepatide and why Monjaro got the FDAs green light for diabetes treatment is its ability to help with insulin levels

COVID-19 and the concept of thrombo-inflammation: Review of the relationship between immune response, endothelium and coagulation

While MPNST remains a challenging malignancy, several promising advances are underway: MEK Inhibitors in NF1-Associated MPNST Given the dysregulation of the RAS/RAF/MEK pathway in NF1-related tumors, MEK inhibitors like selumetinib have shown efficacy in benign plexiform neurofibromas

For all of last year, Cignas net income nearly doubled to $5.95 billion, or $22.18 per share compared to $3.4 billion, or $12.12 per share for 2024, which included a one-time non-cash after-tax investment loss of $2.7 billion, or $9.53 per share, Cigna said

The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases